Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd Valuation

Q: What is the Fair Price of 301130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

301130 (CN¥26.36) is trading above our estimate of [[fair value]] (CN¥6.53)

Is 301130 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301130 (CN¥26.36) is trading above our estimate of fair value (CN¥6.53)

Significantly Below Fair Value: 301130 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301130?

Key metric: As 301130 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301130. This is calculated by dividing 301130's market cap by their current earnings.
What is 301130's PE Ratio?
PE Ratio	46.6x
Earnings	CN¥43.27m
Market Cap	CN¥2.02b

301130 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.7x
Enterprise Value/EBITDA	39.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 301130's PE Ratio compare to its peers?

The above table shows the PE ratio for 301130 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	44.4x
002826 Tibet AIM Pharm	60.8x	n/a	CN¥2.0b
002873 Guiyang Xintian PharmaceuticalLtd	39.1x	28.5%	CN¥2.1b
300519 Zhejiang Xinguang Pharmaceutical	51.2x	n/a	CN¥2.2b
300254 ShanXi C&Y Pharmaceutical GroupLTD	26.7x	n/a	CN¥2.2b
301130 Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd	46.6x	n/a	CN¥2.0b

Price-To-Earnings vs Peers: 301130 is expensive based on its Price-To-Earnings Ratio (46.6x) compared to the peer average (44.4x).

Price to Earnings Ratio vs Industry

How does 301130's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 301130 is expensive based on its Price-To-Earnings Ratio (46.6x) compared to the CN Pharmaceuticals industry average (31.1x).

Price to Earnings Ratio vs Fair Ratio

What is 301130's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301130 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	46.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301130's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%